TIlE FIRST EDITORIAL of the "Critical CareTherapeutics" columnappeared in the May 1982issue of thisjournal,I withthe inaugural article writtenby Thomas C. Majerus, Pharm.D., appearingin the June 1982 issue.' The introductory editorial concluded by stating, "It is hoped that this column will stimulateinterest in critical care, benefit those already involved, and help establish critical care as an important therapeutic area for clinical pharmacy,"! There have been 33 articles published to date in this column on a wide variety of critical care topicsand it remainsthe only column in the pharmacy literature devoted to criticalcare. In keeping with the titles of other columns in this journal, the word "therapeutics" appearsredundant; therefore, the new name of this column is "CriticalCare."
Much has happenedin pharmacy and critical care medicine during the past ten years. For example, critical care has developed into a specialty practicein whichphysicians can now become board certified. Pharmacists are beginning to develop comprehensive pharmaceutical care services in a wide variety of adult, pediatric, and neonatalintensive care units (lCUS).3-7 On the tenth anniversary of the "Critical Care" column, I would like to briefly update readerson the status of criticalcare pharmacy practice, review the accomplishments of pharmacists practicing in this area, and suggest a process for criticalcare pharmacists to gain an appropriate level of recognition and supportfor effective delivery of pharmaceutical care to critically ill patients.
Drug use patterns have been determined in several types of ICUs. [8] [9] [10] [11] As expected, drugs that are commonly prescribedin these patients includeantibiotics, analgesics, antiarrhythmics, vasoactive agents,sedatives, and stressulcer prevention agents. The average number of medications prescribed per day varies from 5.6 to 8.6 (absolute range 1-18) and the average number of total drugs prescribed during the patient's stay is 7.6 to 12.2 (absolute range 1-44). Drug therapy in ICU patients is costly and accounts for nearly 14 percent of hospital charges," With the potentiallarge use of biotechnology drugs in the ICU, these costs are likelyto increase dramatically. The appropriateness of drug therapy and the potential for drug interactions and adverseeffects have not been fully evaluated in critically ill patients. Studies of general hospitalizedpatientscontinueto report that inpatients receive less than optimal pharmacotherapy. For example, a 1991 studyreportedan incidence of prescribing errorsup to 3.13 per 1000 orders written in a large teaching hospital." Althoughit is tempting to assume that drug prescribing in the ICU for patients with complexmedical problems and multiple drug therapy may be worse, studies are neededto assess the appropriateness of pharmacotherapy in this setting.
Critical care pharmacists have increased in numberover the past decadeand have formedspecialty groupsin several professional organizations. Operatingroom (OR) satellite pharmacists, for example, have formed an OR Satellite Pharmacy Association. A survey revealed significant growth in this area of pharmacy practice." The American Societyof Hospital Pharmacists (ASHP) has implemented a Specialty PracticeGroupin Critical Care Pharmacy practice and the American College of Clinical Pharmacy has formed a PracticeResearchNetworkin criticalcare. Each group has approximately 70-80 members. In 1989, a Clinical Pharmacology and Pharmacy Section was formed in the Society of Critical Care Medicine (SCCM).14 There are currently over 80 members (mostly pharmacists),and six pharmacists have beenelectedas Fellows of SCCM.These groups form the nucleus of organized critical care pharmacy practice. Networks of practitioners have beendeveloped and members of the various organizations learn about and participatein a wide variety of activitiesof the respective groups. Approximately 12 postdoctoral criticalcare pharmacy residencies or fellowships currently exist. The ASHP continues to administer a fellowship in critical care pharmacy practice. Standards for a criticalcare pharmacy residency have been published.IS All of these developments make it clear that critical care pharmacy has matured in the last decade.
A national survey of critical care pharmacy services in 613 hospitals identified 764 ICU pharmacists withan addi-tional301 full-time equivalent ICU pharmacists, and the development of 34 more ICU satellite pharmacies anticipated in the following two years. Unit-doseserviceswere available to more than 85 percentof ICU patients; howev-er, only 48-63 percent of the hospitals in this survey reported complete intravenous admixture services to ICU patients, depending on the presence of an ICU satellite pharmacy. Intensive care unit pharmacists in this survey were involved with concurrent review of drug orders, pharmacokinetic consultations, cardiopulmonary resuscitation, calculation of infusion rates, cost-containment programs, provision of nursing inservices, and precepting pharmacy students. 16 The level of agreement on various standards proposed for critical care pharmacy practice was also assessed in this survey. Respondents agreed, on average, with the need for providing 24-hour unit-dose and intravenous admixture services, preparing and monitoring parenteral nutrient products, providing written pharmacokinetic consultations, and preparing inservice education programs for nurses or physicians. However, the respondents were undecided on their degree of agreement of other proposed standards such as 24-hour ICU satellite pharmacy services, clinical pharmacists with 50 or 75 percent of their time devoted to providing clinical services, and a pharmacist being a member of the cardiac arrest team." A recent editorial in the medical literature summarized the contributions of critical care pharmacists and proposes both essential and optimal pharmaceutical services that should be delivered to critically ill patients.' It is hoped that physicians reading this commentary will discuss these issues with pharmacists at their institutions.
ICU pharmacists collaborate with physicians in drug-related research and publish their fmdings in pharmacy and medical journals. My review of CriticalCare Medicine from 1989 to 1991, for example, revealed 37 articles (excluding letters-to-the-editor) with pharmacist authors; in 18 of those articles, a pharmacist was the first author. Pharmacists also are editors of acute care textbooks or authors of chapters on various topics in several critical care medicine textbooks.":"
Quantifying and isolating the impact of critical care pharmacists on patient care is difficult as studies often use historical controls and make assumptions on therapy in the absence of pharmacist intervention. Although the pharmaceutical care concept dictates performing pharmacy functions in relation to patients' outcome or quality of life, quantifying the effect of these interventions is further hampered by the myriad of factors that influence the mortality rate and quality of life of critically ill patients. The presence of a physician with formal training in critical care medicine, however, has been shown to decrease the mortality rate in septic shock patients." Indirect methods, such as cost avoidance, are often used to assess critical care pharmaceutical services.
Although there have been many publications evaluating the impact of clinical pharmacy services in hospitalized patients only a few have been conducted in critically ill patients. 22 ,23 Physician acceptance of clinical pharmacist recommendations and cost savings from optimization of drug therapy often are used as the endpoints in these studies. For example, a pharmacist intervention program increased the percentage of albumin prescribed appropriately and resulted in annualized cost savings of over $83000. 24 As members of the cardiopulmonary resuscitation team, pharmacists have been evaluated by physicians and nurses and defmed as important contributors and necessary members of this team," Physician acceptance of pharmacists providing on-call clinical pharmacy services was evaluated in an emergency department setting. More than 91 percent of the 2000 drug-related recommendations by pharmacists over a two-year period were accepted unchanged by the physicians."
Examples of pharmacist interventions in the ICU include appropriate discontinuation of drug therapy, changes in drug therapy to equally effective and less costly regimens, preventing unnecessary laboratory tests, and detecting and minimizing problems relating to drug therapy."?' Cost savings in these studies are substantial with annualized values ranging from $18 000 to over $500 000. With the high cost of drugs and increased severity of illness of critically ill patients, even infrequent interventions could have signifIcant impact. For example, a new part-time pharmacist with only two hours per day allocated to the ICU of a community hospital saved over $18 000 annually." The effect of pharmacist management of fluid therapy in fluid-restricted ICU patients receiving parenteral nutrition was compared with a group of patients not managed by the pharmacist. The fluid intake of the patients receiving pharmacist monitoring was signifIcantly less than that of the control patients, with similar fluid-output values in both groups. It was concluded that pharmacist involvement in ICU fluid-restricted patients resulted in better fluid balance."
It appears that pharmacists have made significant advances in various ICUs nationally, and have clearly and consistently documented a reduction in drug-related costs. Factors such as polypharmacy, altered drug disposition in ICU patients, and an exploding drug knowledge base highlight the need for a pharmacotherapy specialist to evaluate and implement optimal drug therapy. However, the pharmacist was noticeably absent in a 1984 survey of personnel, facilities, and services in ICUs. 33 A 1988 task force on guidelines for services and personnel in ICUs listed the necessity of 24-hour pharmacy services. This recommendation was included in the "other" category, along with housekeeping and the unit clerk." The scope of these services was not delineated and it could be interpreted simply as providing drugs to ICU patients without the necessary prospective cognitive monitoring and follow-up care.
It would be unconscionable to run an ICU without physicians, nurses, and drugs. However, many ICUs do not employ pharmacists whose primary responsibility is optimizing pharmacotherapy. A study of 167 serum drug concentrations in surgical ICU patients revealed that 42 percent of the samples were considered inappropriate." This type of information has been used in proposals to justify critical care pharmacy services." With the current shift in healthcare to include assessment and accountability of services, it is imperative that both effective drug-delivery systems and clinical pharmacy care be defmed as necessary components of ICU pharmacy services. The logistics of implementing this care will vary with the size of the ICU and the status of the patients. In smaller hospitals with small or distributed ICUs, the pharmacist may have both distribution system and clinical responsibilities. There may not be a full-time intensive care physician in this setting, and the critical care pharmacist can provide an important level of continuity of patient care. Larger ICUs with high patient acuity may requiremultiple ICU pharmacists, some with primary dispensing functions, and others whose re-sponsibility is providing optimal pharmacotherapeutic regimens and outcomes. These individuals need to have a good communication network and a mechanism to crosscover responsibilities, as needed."
The critical care pharmacist must have a close working relationship with the myriad of multidisciplinary professionals who also provide care to the ICU patients. This relationship is necessary to achieve positive outcomes for conditions amenable to pharmacotherapy as physicians, nurses, and respiratory therapists are also involved with the drug therapy process. ICU pharmacists can continue to perform their pharmaceutical care responsibilities by early, aggressive dosing of the aminoglycosides and other antibiotics in septic shock patients; developing dosing regimens of drugs in patients receiving various dialysis techniques; assuring the accuracy of drug therapy administered by all routes, including inhalation; assuring accurate timing of samples for drug concentration measurement, and proper interpretation of the results of serum drug concentrations; assessing changes in physiology and the consequences of altered pharmacokinetics and pharmacodynamics; and optimizing pharmacotherapy with agents such as inotropes and vasoactive drugs, analgesics, anxiolytics, neuromuscular blockers, drugs for stress ulcer prevention, antiarrhythmics, antihypertensives, diuretics, colloids and crystalloids, and nutritional products.
For hospitals to expect an optimal level of ICU phannaceutical services, ICU pharmacists must continue to document and publish their contributions on cost-containment and quality of care. Because cost-eontainment has received considerable attention in the literature, more emphasis should be placed on documenting the quality of pharmacotherapeutic involvement and associated outcomes. It is imperative that ICU pharmacists accept primary responsibility for the delivery of optimal pharmacotherapy to critically ill patients. This requires an appropriate knowledge base and experience in critical care drug therapy and allocation of sufficient time to devote to this type of care. The pharmacist must become the essential component of the multidisciplinary critical care team that deals with all issues related to pharmacotherapy, Demonstrating and documenting the acceptance of this responsibility is essential to deliver optimal pharmaceutical care to ICU patients.'>
